07/02/2016 16:54:48 1-888-992-3836 (toll free) Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
02/02/20164:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
Total Revenues of $193.3 Million Adjusted Diluted EPS of $0.45 and Diluted EPS of $0.41 Company Maintains Fiscal Year 2016 Revenue Guidance, Raises Fiscal Year 2016 Earnings Guidance and Provides Fiscal Third-Quarter 2016 Financial Guidance SALT LAKE CITY, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN... More...>>
01/21/20164:05PMGLOBEMyriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2
SALT LAKE CITY, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee... More...>>
01/07/20167:05AMGLOBEMyriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium
SALT LAKE CITY, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be highlighted on prostate and renal cancers at the 2016 ASCO Genitourinary Cancers Symposium, January 7-9, in San Francisco, Calif. ... More...>>
01/04/20165:00PMGLOBEMyriad Genetics to Present at the 34th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 34th annual J.P. Morgan Healthcare Conference at 9:30 a.m. PST (12:30 pm EST) on January 11, 2016, at the Westin St. Francis in San... More...>>
12/10/20157:05AMGLOBEmyChoice HRD(TM) Test Identifies Breast Cancer Patients Likely to Respond to Platinum-Containing Therapies
SALT LAKE CITY, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be presented demonstrating the role of the myChoice HRD companion diagnostic in identifying patients with breast cancer who are likely to... More...>>
12/09/20157:05AMGLOBEMultiple Scientific Presentations at the San Antonio Breast Cancer Symposium Highlight the Clinical Utility of the Myriad myR...
SALT LAKE CITY, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will highlight three scientific presentations related to its myRisk Hereditary Cancer test at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San... More...>>
12/01/20157:05AMGLOBEUnited States Patent and Trademark Office Grants Patent for Vectra(R) DA
SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual... More...>>
11/17/20157:05AMGLOBEMyriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium
New Data on the myChoice® HRD and myRisk™ Hereditary Cancer Tests Will be Highlighted SALT LAKE CITY, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it will present eight posters at the 2015 San Antonio... More...>>
11/16/20157:05AMGLOBEMyriad RBM DiscoveryMAP(R) Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in...
SALT LAKE CITY, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that its DiscoveryMAP® platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes... More...>>
11/07/20157:30PMGLOBECrescendo Bioscience Announces That New Studies With Vectra(R) DA Data Will be Presented at the American College of Rheumatol...
SALT LAKE CITY, Nov. 7, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at the American College of Rheumatology/Association... More...>>
11/07/20159:20AMTMFGenomic Health, Inc. on Path to Profitability
http://www.fool.com/investing/general/2015/11/07/genomic-health-inc-on-path-to-profitability.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/03/20154:05PMGLOBEMyriad Genetics Reports Fiscal First-Quarter 2016 Financial Results
Total Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk™ Hereditary Cancer Company Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidance SALT LAKE CITY, Nov. 3, 2015 (GLOBE... More...>>
11/01/201511:23AMTMF5 Healthcare Trends to Invest in for the Next 20 Years
http://www.fool.com/investing/general/2015/11/01/5-healthcare-trends-to-invest-in-for-the-next-20-y.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
10/28/20157:05AMGLOBEMyriad Genetics to Present at the 2015 Credit Suisse Healthcare Conference
SALT LAKE CITY, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 24th Annual Credit Suisse Healthcare Conference at 5:00 pm EST on November 11, 2015, at the Phoenician Resort in Phoenix, Arizona... More...>>
10/22/20157:05AMGLOBECrescendo Bioscience Highlights New Studies With Vectra(R) DA That Will Be Presented at the American College of Rheumatology ...
SALT LAKE CITY, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on Vectra DA will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held Nov... More...>>
10/21/20157:05AMGLOBEMyriad Will Highlight New Data on Its myRisk(TM) Hereditary Cancer Test at the National Society of Genetic Counselors Annual ...
SALT LAKE CITY, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data on its myRisk™ Hereditary Cancer molecular diagnostic test will be featured in five presentations at the National Society of Genetic Counselors... More...>>
10/20/20157:05AMGLOBEMyriad to Announce Fiscal First Quarter 2016 Financial Results on November 3, 2015
SALT LAKE CITY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal first-quarter 2016 and provide a business update following the close of market on Tuesday, November 3, 2015. The Company also will host a conference call at 4:30 p.m... More...>>
10/09/20157:05AMGLOBEMyriad to Present New Data on Its myRisk(TM) Hereditary Cancer Test at the CGA-ICC Annual Meeting
SALT LAKE CITY, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present new data on its myRisk™ Hereditary Cancer molecular diagnostic test at the 18th Annual Meeting of the Collaborative Group of the... More...>>
10/08/20157:05AMGLOBEMyriad Genetics to Highlight New Clinical Outcomes Data on myPath(R) Melanoma at the American Society of Dermatopathology Ann...
SALT LAKE CITY, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new clinical outcomes and clinical utility data for myPath® Melanoma will be featured at the American Society of Dermatopathology (ASDP) 52nd meeting... More...>>
10/07/20157:05AMGLOBEMyriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer
SALT LAKE CITY, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20160207 21:54:50